PE20221273A1 - Receptores del antigeno quimerico anti-cd79, celulas car-t, y usos de estos - Google Patents

Receptores del antigeno quimerico anti-cd79, celulas car-t, y usos de estos

Info

Publication number
PE20221273A1
PE20221273A1 PE2022000809A PE2022000809A PE20221273A1 PE 20221273 A1 PE20221273 A1 PE 20221273A1 PE 2022000809 A PE2022000809 A PE 2022000809A PE 2022000809 A PE2022000809 A PE 2022000809A PE 20221273 A1 PE20221273 A1 PE 20221273A1
Authority
PE
Peru
Prior art keywords
seq
amino acid
acid sequence
heavy chain
cd8a
Prior art date
Application number
PE2022000809A
Other languages
English (en)
Inventor
Rajkumar Ganesan
Elena Lasorsa
Ulrike Philippar
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of PE20221273A1 publication Critical patent/PE20221273A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE REFIERE A UN RECEPTOR DE ANTIGENO QUIMERICO (CAR) QUE COMPRENDE: A) UN DOMINIO EXTRACELULAR QUE SE UNE ESPECIFICAMENTE AL ANTIGENO DE CD79B QUE COMPRENDE UNA CDR1 DE CADENA PESADA QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEC ID NO: 208, UNA CDR2 DE CADENA PESADA QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEC ID NO: 209, Y UNA CDR3 DE CADENA PESADA QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEC ID NO: 210; B) UN DOMINIO TRANSMEMBRANA QUE COMPRENDE UN POLIPEPTIDO DE LA REGION TRANSMEMBRANA CD8a (CD8a-TM) CUYA SECUENCIA DE AMINOACIDOS ES DE SEC ID NO: 39; C) UN DOMINIO DE SENALIZACION INTRACELULAR QUE COMPRENDE OPCIONALMENTE AL MENOS UN DOMINIO COESTIMULADOR CUYA SECUENCIA DE AMINOACIDOS ES DE SEC ID NO: 40; Y D) UNA REGION BISAGRA DE CD8a QUE COMPRENDE UNA SECUENCIA DE AMINOACIDOS DE SEC ID NO: 38. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE CANCER.
PE2022000809A 2019-11-18 2020-11-17 Receptores del antigeno quimerico anti-cd79, celulas car-t, y usos de estos PE20221273A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962936662P 2019-11-18 2019-11-18
PCT/IB2020/060826 WO2021099944A1 (en) 2019-11-18 2020-11-17 Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof

Publications (1)

Publication Number Publication Date
PE20221273A1 true PE20221273A1 (es) 2022-09-01

Family

ID=73598921

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000809A PE20221273A1 (es) 2019-11-18 2020-11-17 Receptores del antigeno quimerico anti-cd79, celulas car-t, y usos de estos

Country Status (18)

Country Link
US (1) US20210145878A1 (es)
EP (1) EP4061837A1 (es)
JP (1) JP2023502652A (es)
KR (1) KR20220114560A (es)
CN (1) CN114945590A (es)
AU (1) AU2020387709A1 (es)
BR (1) BR112022009602A2 (es)
CA (1) CA3161825A1 (es)
CL (1) CL2022001299A1 (es)
CO (1) CO2022008484A2 (es)
CR (1) CR20220221A (es)
DO (1) DOP2022000102A (es)
EC (1) ECSP22048631A (es)
IL (1) IL293046A (es)
JO (1) JOP20220117A1 (es)
MX (1) MX2022005983A (es)
PE (1) PE20221273A1 (es)
WO (1) WO2021099944A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
CA3214259A1 (en) * 2021-03-24 2022-09-29 Janssen Biotech, Inc. Antibody targeting cd22 and cd79b
US20230094867A1 (en) * 2021-06-01 2023-03-30 Janssen Biotech, Inc. Anti-idiotypic antibodies against anti-cd79b antibodies
WO2024097901A1 (en) * 2022-11-02 2024-05-10 Fate Therapeutics, Inc. Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting cd79b

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US20020197266A1 (en) 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
CA2490280A1 (en) * 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
WO2004111233A1 (ja) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha 抗体の製造方法
AU2006208286A1 (en) * 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2006113665A2 (en) 2005-04-15 2006-10-26 Macrogenics, Inc. Covalent diabodies and uses thereof
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CN104497143B (zh) 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
CN102112492B (zh) * 2007-11-14 2015-02-25 中外制药株式会社 使用抗gpr49抗体的癌症的诊断和治疗
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
ES2774337T3 (es) 2008-01-07 2020-07-20 Amgen Inc Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
WO2010011860A1 (en) * 2008-07-23 2010-01-28 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes
US20100143349A1 (en) * 2008-08-12 2010-06-10 Wyeth Humanized anti-rage antibody
WO2010059543A1 (en) * 2008-11-20 2010-05-27 Merck Sharp & Dohme Corp. Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2010141249A2 (en) * 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-notch3 antibodies
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
EP2496600A1 (en) * 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
RS65965B1 (sr) 2010-04-20 2024-10-31 Genmab As Proteini koji sadrže fc heterodimernih antitela i postupci njihove proizvodnje
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
AU2015254558B2 (en) * 2014-05-02 2021-02-25 Medimmune Limited Ion channel modulators and uses thereof
JP6961490B2 (ja) * 2015-04-08 2021-11-05 ノバルティス アーゲー Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
WO2017049038A2 (en) * 2015-09-16 2017-03-23 Ablexis, Llc Anti-cd115 antibodies
WO2017058944A1 (en) * 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors
EP3808764A1 (en) * 2016-05-04 2021-04-21 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
AU2018279085A1 (en) * 2017-06-07 2019-12-05 Region Of Southern Denmark T cells expressing a chimeric antigen receptor
JP7095078B2 (ja) 2017-09-22 2022-07-04 カイト ファーマ インコーポレイテッド キメラポリペプチド及びその使用
CA3082321A1 (en) * 2017-11-13 2019-05-16 Crescendo Biologics Limited Single domain antibodies that bind to cd137
US11401336B2 (en) * 2018-02-21 2022-08-02 Celgene Corporation BCMA-binding antibodies and uses thereof
GB201807870D0 (en) * 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
JP7335272B2 (ja) * 2018-05-15 2023-08-29 オートラス リミテッド キメラ抗原受容体
WO2019241688A1 (en) * 2018-06-14 2019-12-19 Bluebird Bio, Inc. Cd79b chimeric antigen receptors
CN109265565B (zh) * 2018-10-10 2021-06-01 苏州大学 一种携带分子开关的抗CD79b嵌合抗原受体及其修饰的免疫细胞和应用
WO2020124021A1 (en) * 2018-12-13 2020-06-18 The General Hospital Corporation Chimeric antigen receptors targeting cd79b and cd19

Also Published As

Publication number Publication date
CL2022001299A1 (es) 2023-03-03
CR20220221A (es) 2022-07-11
EP4061837A1 (en) 2022-09-28
MX2022005983A (es) 2022-09-07
JP2023502652A (ja) 2023-01-25
ECSP22048631A (es) 2022-07-29
DOP2022000102A (es) 2022-09-30
CA3161825A1 (en) 2021-05-27
CN114945590A (zh) 2022-08-26
CO2022008484A2 (es) 2022-06-30
KR20220114560A (ko) 2022-08-17
BR112022009602A2 (pt) 2022-09-20
US20210145878A1 (en) 2021-05-20
IL293046A (en) 2022-07-01
WO2021099944A1 (en) 2021-05-27
JOP20220117A1 (ar) 2023-01-30
AU2020387709A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
PE20221273A1 (es) Receptores del antigeno quimerico anti-cd79, celulas car-t, y usos de estos
MX2020011391A (es) Anticuerpo bcma humanizado y linfocitos t car-bcma.
PE20220495A1 (es) Receptores antigenicos quimericos y agentes de union dirigidos a dll3
PE20241061A1 (es) Polinucleotidos que codifican receptores de antigeno quimericos de flt3
AR126242A2 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
NZ750366A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
HRP20211081T1 (hr) Anti-pro/latentna miostatinska protutijela i njihove uporabe
PE20241587A1 (es) Receptores de antigenos quimericos que se dirigen a flt3
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
WO2017172981A3 (en) Chimeric antigen receptors targeting cancer
PE20121689A1 (es) Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
PE20081214A1 (es) Anticuerpo especifico prlr y sus usos
PE20190975A1 (es) Novela cd47 anticuerpos monoclonales y sus usos
AR095115A1 (es) Anticuerpos que comprenden dominios constantes quiméricos
RU2021124437A (ru) Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования
PE20080846A1 (es) Composiciones y metodos relacionados con los anticuerpos receptores de glucagon
PE20211291A1 (es) Anticuerpos anti-ox40 y metodos de uso
AR111830A1 (es) Anticuerpos monoclonales antagonistas contra cd40 y sus usos
PE20140247A1 (es) Anticuerpos anti-cd38
PE20110774A1 (es) Anticuerpos para ccr2
AR077111A1 (es) Proteinas biespecificas tetravalentes de union a antigeno
PE20091269A1 (es) Moleculas de union al receptor ox40 humano
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
PE20160690A1 (es) Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos